Ionis (IONS) Q1 FY26 earnings call

Ionis Pharmaceuticals entered 2026 with significant momentum, continuing its transition into a fully integrated commercial biotech company. The company reported strong Q1 financial results driven by accelerating commercial launches of Tryngolza and DAWNZERA, alongside substantial R&D revenue from partnerships. Management raised its full-year revenue and operating loss guidance, reflecting confidence in its expanding commercial portfolio and advancing pipeline, with a clear path towards cash flow breakeven by 2028.